EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Mannose-labelled magnetic nanoparticles for sentinel lymph node biopsy in oral squamous cell carcinoma: Initial results from a phase 1 clinical trial

Giri Krishnan, Aidan Cousins, Shridhar Krishnan, Deepak Dhatrak, Angela Walls, Andrew Dwyer, Nynke van den Berg, Eben Rosenthal, Anil Shetty, James Badlani, John-Charles Hodge, Suren Krishnan und 2 weitere

European Journal of Surgical Oncology · 2025-09 · 51 (9) · 110221

DOI: 10.1016/j.ejso.2025.110221 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Surgical Oncology, 2025-09. Verfasst von Giri Krishnan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, The University of Adelaide, Adelaide, SA, 5000, Australia. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Sentinel Lymph Node Biopsy, Mannose. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Garnett Passe and Rodney Williams Memorial Foundation, Royal Adelaide Hospital, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Sentinel lymph node biopsy (SLNB) can stage neck disease in oral squamous cell carcinoma (OSCC) with less morbidity than elective neck dissection (END) but is not widely practised because of inherent limitations associated with conventional radiotracers. This study evaluated the feasibility of a next generation magnetic technique. MATERIALS AND METHODS: A phase 1 prospective clinical trial was conducted, recruiting patients with cN0 OSCC. "FerroTrace", a mannose-labelled iron oxide nanoparticle, was injected peritumourally. Patients underwent MRI with pseudo-dynamic and static sequences prior to SLNB aided by handheld magnetometer probe. SLNs were sent for serial-sectioning and patients underwent END in the same procedure as standard of care. RESULTS: Eight patients were enrolled with T2 lesions located in the tongue (4/8), retromolar trigone (3/8) or floor of mouth (1/8). An average of 4.1 ± 1.5 (n = 33) magnetic LNs per patient were identified via magnetometer probe during surgery, which included SLNs identified on preoperative MRI (2.6 ± 1.4; n = 21). An additional 24.6 ± 10.5 (n = 197) LNs per patient were removed as part of standard of care END. One magnetic LN was confirmed pN+, with all remaining magnetic and END LNs pN0. No adverse events were recorded. CONCLUSION: This study demonstrates the procedural feasibility of a novel magnetic approach to SLNB in OSCC using a first-in-human magnetic tracer. These promising early results lay the foundation for an attractive next generation technique, and holds significant potential to increase adoption of SLNB in the complex head and neck lymphatic environment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsSentinel Lymph Node BiopsyMannoseMagnetic Iron Oxide NanoparticlesMagnetite NanoparticlesHumansMaleFemaleMiddle AgedProspective StudiesMagnetic Resonance ImagingAgedFeasibility StudiesAdultNeoplasm StagingLymphatic Metastasis

Stichwörter der Autor:innen

Fluorescent molecular imagingHead and neck cancerMagnetic particlesNanotechnologyOral cancerSentinel lymph node biopsy

Substanzen

MannoseMagnetite Nanoparticles

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, The University of Adelaide, Adelaide, SA, 5000, Australia.
  • Future Industries Institute, University of South Australia, Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia; Ferronova Pty Ltd, MM-building, UniSA Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia.
  • Department of Oral and Maxillofacial Surgery, The University of Adelaide, Adelaide, SA, 5000, Australia.
  • Department of Surgical Pathology, The University of Adelaide, Adelaide, SA, 5000, Australia.
  • Clinical and Research Imaging Centre, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
  • Department of Otolaryngology - Division of Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, United States.

Förderung

  • Garnett Passe and Rodney Williams Memorial Foundation
  • Royal Adelaide Hospital
  • National Health and Medical Research Council

Zitieren

APA

Krishnan, G., Cousins, A., Krishnan, S., Dhatrak, D., Walls, A., Dwyer, A., van den Berg, N., Rosenthal, E., Shetty, A., Badlani, J., Hodge, J. C., Krishnan, S., Foreman, A., & Thierry, B. (2025). Mannose-labelled magnetic nanoparticles for sentinel lymph node biopsy in oral squamous cell carcinoma: Initial results from a phase 1 clinical trial. European Journal of Surgical Oncology, 51(9), 110221. https://doi.org/10.1016/j.ejso.2025.110221

Vancouver

Krishnan G, Cousins A, Krishnan S, Dhatrak D, Walls A, Dwyer A, et al. Mannose-labelled magnetic nanoparticles for sentinel lymph node biopsy in oral squamous cell carcinoma: Initial results from a phase 1 clinical trial. European Journal of Surgical Oncology. 2025;51(9):110221. doi:10.1016/j.ejso.2025.110221

BibTeX
@article{Krishnan2025,
  author = {Krishnan, Giri and Cousins, Aidan and Krishnan, Shridhar and Dhatrak, Deepak and Walls, Angela and Dwyer, Andrew and van den Berg, Nynke and Rosenthal, Eben and Shetty, Anil and Badlani, James and Hodge, John-Charles and Krishnan, Suren and Foreman, Andrew and Thierry, Benjamin},
  title = {Mannose-labelled magnetic nanoparticles for sentinel lymph node biopsy in oral squamous cell carcinoma: Initial results from a phase 1 clinical trial},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  volume = {51},
  number = {9},
  pages = {110221},
  doi = {10.1016/j.ejso.2025.110221}
}
Kostenlos starten →